Abemaciclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section	Indications
Targeted therapies ◦ Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Axitinib

Section	Indications
Targeted therapies ◦ Oral > Solid > tablet: 1 mg; 3 mg; 5 mg	Renal cell carcinoma of kidney, except renal pelvis

Binimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib pour Other specified melanoma of skin

Bortezomib

Section	Indications
Targeted therapies ◦ Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Cobimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib pour Other specified melanoma of skin

Crizotinib

Section	Indications
Targeted therapies ◦ Oral > Solid > capsule: 200 mg; 250 mg ◦ Oral > Solid: 200 mg; 250 mg	Anaplastic large cell lymphoma, ALK-positive Other specified malignant neoplasms of bronchus or lung

Dabrafenib

Section	Indications
Targeted therapies ◦ Oral > Solid: 50 mg; 75 mg	Other specified melanoma of skin

Dasatinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet	Chronic myelogenous leukaemia, BCR-ABL1-positive

Encorafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin

Erlotinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 100 mg; 150 mg	Other specified malignant neoplasms of bronchus or lung

Everolimus

Section	Indications
Targeted therapies ◦ Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg ◦ Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg	Other specified gliomas of brain

Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung

Ibrutinib

Section	Indications
Targeted therapies - Oral > Solid: 140 mg	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Imatinib

Section	Indications
Targeted therapies - Oral > Solid: 100 mg; 400 mg	B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1 Chronic myeloid leukaemia, not elsewhere classified Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Lenvatinib

Section	Indications
Targeted therapies - Oral > Solid > capsule: 4 mg; 10 mg	Renal cell carcinoma of kidney, except renal pelvis

Nilotinib

Section	Indications
Targeted therapies - Oral > Solid > capsule: 150 mg; 200 mg	Chronic myelogenous leukaemia, BCR-ABL1-positive

Osimertinib

Section	Indications
Targeted therapies - Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)	Other specified malignant neoplasms of bronchus or lung

Palbociclib

Section	Indications
Targeted therapies - Oral > Solid: 75 mg; 100 mg; 125 mg	Other specified malignant neoplasms of breast

Panitumumab

Section	Indications
Targeted therapies - Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial	Other specified malignant neoplasms of large intestine

Pertuzumab

Section	Indications
Targeted therapies - Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution	Carcinoma of breast, specialised type

Ribociclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast

Rituximab

Section	Indications
Targeted therapies - Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial	Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Burkitt lymphoma including Burkitt leukaemia Follicular lymphoma

Trametinib

Section	Indications
Targeted therapies - Oral > Solid: 0.5 mg; 2 mg	Other specified melanoma of skin

Trastuzumab

Section	Indications
Targeted therapies - Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection	Carcinoma of breast, specialised type

Trastuzumab emtansine

Section	Indications
Targeted therapies ◦ Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection	Carcinoma of breast, specialised type

Vemurafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib pour Other specified melanoma of skin

Zanubrutinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 80 mg ◦ Oral > Solid > capsule: 80 mg	Mantle cell lymphoma Therapeutic equivalent to ibrutinib pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma